These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


600 related items for PubMed ID: 25770169

  • 1. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB, Martin KJ.
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [Abstract] [Full Text] [Related]

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Apr; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 3. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ, González EA.
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [Abstract] [Full Text] [Related]

  • 4. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V, Longhitano E, Calabrese V, Casuscelli C, Di Carlo S, Spinella C, Gembillo G, Santoro D.
    Expert Opin Pharmacother; 2023 Feb; 24(15):1737-1746. PubMed ID: 37527180
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A, Cozzolino M, Adragao T, Di Iorio B, Russo D.
    J Nephrol; 2013 Feb; 26(6):993-1000. PubMed ID: 23543481
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, IMPROVE-CKD Writing Committee..
    BMJ Open; 2019 Feb 21; 9(2):e024382. PubMed ID: 30796122
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct 21; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 14. Niacin and Chronic Kidney Disease.
    Taketani Y, Masuda M, Yamanaka-Okumura H, Tatsumi S, Segawa H, Miyamoto K, Takeda E, Yamamoto H.
    J Nutr Sci Vitaminol (Tokyo); 2015 Oct 21; 61 Suppl():S173-5. PubMed ID: 26598845
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action.
    Calvo MS, Sherman RA, Uribarri J.
    Am J Kidney Dis; 2019 Apr 21; 73(4):542-551. PubMed ID: 30686528
    [Abstract] [Full Text] [Related]

  • 20. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 30.